37 results on '"Ahmed, Hashim U."'
Search Results
2. Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer
- Author
-
Dikaios, Nikolaos, Giganti, Francesco, Sidhu, Harbir S., Johnston, Edward W., Appayya, Mrishta B., Simmons, Lucy, Freeman, Alex, Ahmed, Hashim U., Atkinson, David, and Punwani, Shonit
- Published
- 2019
- Full Text
- View/download PDF
3. “Textural analysis of multiparametric MRI detects transition zone prostate cancer”
- Author
-
Sidhu, Harbir S., Benigno, Salvatore, Ganeshan, Balaji, Dikaios, Nikos, Johnston, Edward W., Allen, Clare, Kirkham, Alex, Groves, Ashley M., Ahmed, Hashim U., Emberton, Mark, Taylor, Stuart A., Halligan, Steve, and Punwani, Shonit
- Published
- 2017
- Full Text
- View/download PDF
4. Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies
- Author
-
Lee, Daniel J., Ahmed, Hashim U., Moore, Caroline M., Emberton, Mark, and Ehdaie, Behfar
- Published
- 2014
- Full Text
- View/download PDF
5. PD39-01 THE SUITABILITY OF HEMI-ABLATION FOR PATIENTS DIAGNOSED WITH LOCALISED PROSTATE CANCER FOLLOWING MULTIPARAMETRIC MRI TARGETED AND NON-TARGETED TRANSPERINEAL PROSTATE BIOPSY.
- Author
-
Reddy, Deepika, Eldred-Evans, David, Winkler, Mathias, Shah, Taimur, and Ahmed, Hashim U.
- Subjects
PROSTATE biopsy ,PROSTATE cancer ,MAGNETIC resonance imaging ,DELPHI method ,DIAGNOSIS - Published
- 2024
- Full Text
- View/download PDF
6. Role of multiparametric prostate MRI in the management of prostate cancer.
- Author
-
O'Connor, Luke P., Lebastchi, Amir H., Horuz, Rahim, Rastinehad, Ardeshir R., Siddiqui, M. Minhaj, Grummet, Jeremy, Kastner, Christof, Ahmed, Hashim U., Pinto, Peter A., and Turkbey, Baris
- Subjects
PROSTATE biopsy ,ENDORECTAL ultrasonography ,PROSTATE ,PROSTATE cancer ,MAGNETIC resonance imaging ,DIAGNOSIS - Abstract
Introduction: Prostate cancer has traditionally been diagnosed by an elevation in PSA or abnormal exam leading to a systematic transrectal ultrasound (TRUS)-guided biopsy. This diagnostic pathway underdiagnoses clinically significant disease while over diagnosing clinically insignificant disease. In this review, we aim to provide an overview of the recent literature regarding the role of multiparametric MRI (mpMRI) in the management of prostate cancer. Materials and Methods: A thorough literature review was performed using PubMed to identify articles discussing use of mpMRI of the prostate in management of prostate cancer. Conclusion: The incorporation of mpMRI of the prostate addresses the shortcomings of the prostate biopsy while providing several other advantages. mpMRI allows some men to avoid an immediate biopsy and permits visualization of areas likely to harbor clinically significant cancer prior to biopsy to facilitate use of MR-targeted prostate biopsies. This allows for reduction in diagnosis of clinically insignificant disease as well as improved detection and better characterization of higher risk cancers, as well as the improved selection of patients for active surveillance. In addition, mpMRI can be used for selection and monitoring of patients for active surveillance and treatment planning during surgery and focal therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy
- Author
-
Singh, Paras B., Anele, Chukwuemeka, Dalton, Emma, Barbouti, Omar, Stevens, Daniel, Gurung, Pratik, Arya, Manit, Jameson, Charles, Freeman, Alex, Emberton, Mark, and Ahmed, Hashim U.
- Subjects
Ablation Techniques ,Adult ,Aged, 80 and over ,Male ,Prostate cancer ,Patient Selection ,Biopsy ,Urology ,Biopsy, Fine-Needle ,Platinum Priority – Prostate Cancer ,Prostate ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,Magnetic Resonance Imaging ,Diagnosis ,Pathology ,Humans ,Surgery ,Therapy ,Neoplasm Grading ,Editorial by Luke Dixon, Matthew Brown and Benjamin Challacombe on pp. 20–21 of this issue ,Aged ,Neoplasm Staging - Abstract
Background Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. Objective To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. Design, setting, and participants Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. Intervention TTPM biopsies using a 5-mm sampling frame. Outcome measurements and statistical analysis Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. Results and limitations The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000–0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. Conclusions Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy., Take Home Message When transperineal template prostate-mapping biopsy was applied to men with low- and intermediate-risk prostate cancer, most were found to be suitable for a focal therapy, including the strategy of index lesion ablation in multifocal disease.
- Published
- 2014
- Full Text
- View/download PDF
8. Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis
- Author
-
Willis, Sarah R, Ahmed, Hashim U, Moore, Caroline M, Donaldson, Ian, Emberton, Mark, Miners, Alec H, and van der Meulen, Jan
- Subjects
Image-Guided Biopsy ,Male ,Science & Technology ,STRATEGIES ,decision trees ,diagnosis ,ACCURACY ,SYSTEMATIC BIOPSY ,Prostate ,Prostatic Neoplasms ,RESONANCE ,Magnetic Resonance Imaging ,Decision Support Techniques ,FUSION BIOPSY ,Medicine, General & Internal ,General & Internal Medicine ,Humans ,biopsy ,Life Sciences & Biomedicine - Abstract
OBJECTIVE: To compare the diagnostic outcomes of the current approach of transrectal ultrasound (TRUS)-guided biopsy in men with suspected prostate cancer to an alternative approach using multiparametric MRI (mpMRI), followed by MRI-targeted biopsy if positive. DESIGN: Clinical decision analysis was used to synthesise data from recently emerging evidence in a format that is relevant for clinical decision making. POPULATION: A hypothetical cohort of 1000 men with suspected prostate cancer. INTERVENTIONS: mpMRI and, if positive, MRI-targeted biopsy compared with TRUS-guided biopsy in all men. OUTCOME MEASURES: We report the number of men expected to undergo a biopsy as well as the numbers of correctly identified patients with or without prostate cancer. A probabilistic sensitivity analysis was carried out using Monte Carlo simulation to explore the impact of statistical uncertainty in the diagnostic parameters. RESULTS: In 1000 men, mpMRI followed by MRI-targeted biopsy 'clinically dominates' TRUS-guided biopsy as it results in fewer expected biopsies (600 vs 1000), more men being correctly identified as having clinically significant cancer (320 vs 250), and fewer men being falsely identified (20 vs 50). The mpMRI-based strategy dominated TRUS-guided biopsy in 86% of the simulations in the probabilistic sensitivity analysis. CONCLUSIONS: Our analysis suggests that mpMRI followed by MRI-targeted biopsy is likely to result in fewer and better biopsies than TRUS-guided biopsy. Future research in prostate cancer should focus on providing precise estimates of key diagnostic parameters.
- Published
- 2014
9. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
- Author
-
Valerio, Massimo, Dickinson, Louise, Ali, Afia, Ramachadran, Navin, Donaldson, Ian, Mccartan, Neil, Freeman, Alex, Ahmed, Hashim U., and Emberton, Mark
- Subjects
PROSTATE cancer treatment ,ELECTROPORATION therapy ,CATHETER ablation ,PROSTATE biopsy ,DIAGNOSIS ,PROSTATE cancer ,LONGITUDINAL method - Abstract
Purpose Irreversible electroporation has attractive attributes for focal ablation, namely nonthermal effect, precise demarcation of treatment and tissue selectivity. We report a prospective development study investigating focal irreversible electroporation. Materials and Methods A total of 20 men with certain characteristics were recruited for study, including a visible index lesion on anterior magnetic resonance imaging that was concordant with transperineal targeted and template prostate mapping biopsy, absent clinically significant disease noted elsewhere (University College London definition 2) and prostate specific antigen 15 ng/ml or less. Our primary objective was to determine the side effect profile at 12 months. Secondary objectives included the domain specific toxicity profile using patient reported outcomes and early disease control using magnetic resonance imaging targeted biopsy. Results A total of 19 patients with median age of 60 years (IQR 53–66) and median prostate specific antigen 7.75 ng/ml (IQR 5.5–10.03) were treated. Of the patients 16 were available for estimating the first outcome as 1 was lost to followup and 2 had received another form of treatment by study end. All 16 men had pad-free/leak-free continence at 12 months. The proportion of men with erection sufficient for penetration decreased from 12 of 16 (75%) to 11 of 16 (69%). No serious adverse events were recorded. There was a statistically significant improvement in urinary symptoms according to changes in UCLA-EPIC (UCLA Expanded Prostate Cancer Index Composite) and I-PSS (International Prostate Symptom Score) (p = 0.039 and 0.001, respectively). Erectile function remained stable according to the change in IIEF-15 (15-Item International Index of Erectile Function) (p = 0.572). Median prostate specific antigen significantly decreased to 1.71 ng/ml (p = 0.001). One man refused followup biopsy. No residual disease was found in 11 patients (61.1%). One man (5.6%) harbored clinically insignificant disease and the remaining 6 (33.3%) harbored clinically significant disease. Conclusions Focal irreversible electroporation has low genitourinary toxicity. Additional studies are needed to optimize patient selection and treatment parameters. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.
- Author
-
Johnston, Edward, Hayley Pye, Bonet-Carne, Elisenda, Panagiotaki, Eleftheria, Patel, Dominic, Galazi, Myria, Heavey, Susan, Carmona, Lina, Freeman, Alexander, Trevisan, Giorgia, Allen, Clare, Kirkham, Alexander, Burling, Keith, Stevens, Nicola, Hawkes, David, Emberton, Mark, Moore, Caroline, Ahmed, Hashim U., Atkinson, David, and Rodriguez-Justo, Manuel
- Subjects
BIOMARKERS ,DIFFUSION magnetic resonance imaging ,BLOOD serum analysis ,URINALYSIS ,DIAGNOSIS ,PROSTATE cancer ,COHORT analysis - Abstract
Background: Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a significant advance in the diagnosis of prostate cancer, scanning all patients with elevated prostate specific antigen (PSA) levels is considered too costly for widespread National Health Service (NHS) use, as the predictive value of PSA levels for significant disease is poor. Despite the fact that novel blood and urine tests are available which may predict aggressive disease better than PSA, they are not routinely employed due to a lack of clinical validity studies. Furthermore approximately 40 % of mp-MRI studies are reported as indeterminate, which can lead to repeat examinations or unnecessary biopsy with associated patient anxiety, discomfort, risk and additional costs. Methods/Design: We aim to clinically validate a panel of minimally invasive promising blood and urine biomarkers, to better select patients that will benefit from a multiparametric prostate MRI. We will then test whether the performance of the mp-MRI can be improved by the addition of an advanced diffusion-weighted MRI technique, which uses a biophysical model to characterise tissue microstructure called VERDICT; Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours. INNOVATE is a prospective single centre cohort study in 365 patients. mp-MRI will act as the reference standard for the biomarker panel. A clinical outcome based reference standard based on biopsy, mp-MRI and follow-up will be used for VERDICT MRI. Discussion: We expect the combined effect of biomarkers and VERDICT MRI will improve care by better detecting aggressive prostate cancer early and make mp-MRI before biopsy economically viable for universal NHS adoption. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer.
- Author
-
Valerio, Massimo, Anele, Chukwuemeka, Charman, Susan C., Meulen, Jan, Freeman, Alex, Jameson, Charles, Singh, Paras B., Emberton, Mark, and Ahmed, Hashim U.
- Subjects
PROSTATE biopsy ,PROSTATE cancer treatment ,DIAGNOSIS ,PROSTATE cancer ,BIOPSY ,STATISTICAL bootstrapping - Abstract
Objectives To determine whether modified transperineal template prostate-mapping ( TTPM) biopsy protocols, altering the template or the biopsy density, have sensitivity and negative predictive value ( NPV) equal to full 5-mm TTPM. Patients and Methods Retrospective analysis of an institutional registry including treatment-naïve men undergoing 5-mm TTPM biopsy analysed in a 20-zone fashion. The value of three modified strategies was assessed by comparing the information provided by selected zones against full 5-mm TTPM. Strategy 1, did not consider the findings of anterior areas; strategies 2 and 3 simulated a reduced biopsy density by excluding intervening zones. A bootstrapping technique was used to calculate reliable estimates of sensitivity and NPV of these three strategies for the detection of clinically significant disease (maximum cancer core length ≥4 mm and/or Gleason score ≥3 + 4). Results In all, 391 men with a median (interquartile range, IQR) age of 62 (58-67) years were included. The median ( IQR) PSA level and PSA density were 6.9 (4.8-10) ng/mL and 0.17 ( IQR 0.12-0.25) ng/mL/mL, respectively. A median ( IQR) of 6 (2-9) cores out of 48 (33-63) taken per man were positive for prostate cancer. No cancer was detected in 67 men (17%), whilst low-, intermediate- and high-risk disease was identified in 78 (20%), 80 (21%), and 166 (42%), respectively. Strategy 1, 2 and 3 had sensitivities of 78% [95% confidence interval ( CI) 73-84%], 85% (95% CI 80-90%) and 84% (95% CI 79-89%), respectively. The NPVs of the three strategies were 73% (95% CI 67-80%), 80% (95% CI 74-86%) and 79% (95% CI 72-84%), respectively. Conclusion Altering the template or decreasing sampling density has a substantial negative impact on the ability of TTPM biopsy to exclude clinically significant disease. This should be considered when modified TTPM biopsy strategies are used to select men for tissue-preserving approaches, and when modified TTPM are used to validate new diagnostic tests. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Identifying the Index Lesion with Template Prostate Mapping Biopsies.
- Author
-
Valerio, Massimo, Anele, Chukwuemeka, Freeman, Alex, Jameson, Charles, Singh, Paras B., Hu, Yipeng, Emberton, Mark, and Ahmed, Hashim U.
- Subjects
PROSTATE cancer ,DIAGNOSIS ,DRUG tolerance ,PROSTATECTOMY ,BIOPSY ,ULTRASONIC imaging - Abstract
Purpose The natural history of prostate cancer might be driven by the index lesion. We determined the percent of men in whom the index lesion could be defined using transperineal template prostate mapping biopsies. Materials and Methods Included in study were consecutive men undergoing transperineal template prostate mapping biopsies with biopsies grouped into 20 zones. Men with clinically significant disease in only 1 prostate area were considered to have an identifiable index lesion. We evaluated the impact of using 2 definitions of clinically significant disease (Gleason grade pattern 4 and/or lesion volume 0.5 cc or greater) and 2 clustering rules (stringent and tolerant) to define the index lesion. Results Included in study were 391 men with a median age of 62 years (IQR 58–67) and a median prostate specific antigen of 6.9 ng/ml (IQR 4.8–10.0). Of the men 269 (69%) were previously diagnosed with prostate cancer. By deploying a median of 1.2 cores per ml (IQR 0.9–1.7) cancer was diagnosed in 82.9% of the men (324 of 391) with a median of 6 positive cores (IQR 2–9), a median maximum cancer core length of 5 mm (IQR 3–8) and a total cancer core length per zone of 7 mm (IQR 3–13). Insignificant disease was found in 26.3% to 42.9% of cases. When a stringent spatial relationship was used to define individual lesions, 44.4% to 54.6% of patients had 1 index lesion and 12.7% to 19.1% had more than 1 area with clinically significant disease. These proportions changed to 46.6% to 59.2% and 10.5% to 14.5%, respectively, when less stringent spatial clustering was applied. Conclusions Transperineal template prostate mapping biopsies enable the index lesion to be localized in most men with clinically significant disease. This information may be important to select appropriate candidates for targeted therapy and to plan a tailored treatment strategy in men undergoing radical therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Salvage High-intensity Focused Ultrasound for Patients With Recurrent Prostate Cancer After Brachytherapy.
- Author
-
Yutkin, Vladimir, Ahmed, Hashim U., Donaldson, Ian, McCartan, Neil, Siddiqui, Khurram, Emberton, Mark, and Chin, Joseph L.
- Subjects
- *
HIGH-intensity focused ultrasound , *DIAGNOSIS , *PROSTATE cancer , *RADIOISOTOPE brachytherapy , *CANCER relapse , *PROSTATE cancer patients , *PROSTATE cancer treatment - Abstract
Objective To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer. Patients and Methods Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed. Results Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the “nadir prostate-specific antigen level” +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population. Conclusion In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Multi-Parametric Magnetic Resonance Imaging to Rule-In and Rule-Out Clinically Important Prostate Cancer in Men at Risk: A Cohort Study.
- Author
-
Rouse, Paul, Shaw, Greg, Ahmed, Hashim U., Freeman, Alex, Allen, Clare, and Emberton, Mark
- Subjects
DIAGNOSIS ,PROSTATE cancer ,SEX factors in disease ,COHORT analysis ,BIOPSY ,MAGNETIC resonance imaging ,ULTRASONIC imaging ,DISEASE risk factors - Abstract
Objectives: Overdiagnosis is arguably the greatest challenge in the management of men with prostate cancer. Multi-parametric (mp)-MRI prior to prostate biopsy may have a role in ruling-in and ruling-out clinically significant disease. Patients and Methods: 114 consecutive men at risk of prostate cancer with previous biopsy underwent mp-MRI prior to transrectal ultrasound (TRUS)-guided biopsies. Standard systematic biopsies were carried out with targeting to suspicious areas. Results: 59.6% had cancer detected by TRUS-guided biopsy. Mean age was 63.6 years (SD 9.0). If men had not been biopsied because of a negative mp-MRI, 21% (24/114) with no cancer and 5% (6/114) with clinically insignificant cancer could have avoided a biopsy. However, 4% (4/114) would have been advised to defer a biopsy that demonstrated the presence of clinically significant cancer. Conclusion: mp-MRI may have a role in ruling-in and ruling-out clinically significant prostate cancer in men at risk prior to biopsy. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting
- Author
-
Dickinson, Louise, Ahmed, Hashim U., Allen, Clare, Barentsz, Jelle O., Carey, Brendan, Futterer, Jurgen J., Heijmink, Stijn W., Hoskin, Peter J., Kirkham, Alex, Padhani, Anwar R., Persad, Raj, Puech, Philippe, Punwani, Shonit, Sohaib, Aslam S., Tombal, Bertrand, Villers, Arnauld, van der Meulen, Jan, and Emberton, Mark
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *MAGNETIC resonance imaging of cancer , *SERUM , *DIFFUSION magnetic resonance imaging , *IMAGE analysis , *PROSTATE-specific antigen - Abstract
Abstract: Background: Multiparametric magnetic resonance imaging (mpMRI) may have a role in detecting clinically significant prostate cancer in men with raised serum prostate-specific antigen levels. Variations in technique and the interpretation of images have contributed to inconsistency in its reported performance characteristics. Objective: Our aim was to make recommendations on a standardised method for the conduct, interpretation, and reporting of prostate mpMRI for prostate cancer detection and localisation. Design, setting, and participants: A consensus meeting of 16 European prostate cancer experts was held that followed the UCLA-RAND Appropriateness Method and facilitated by an independent chair. Measurement: Before the meeting, 520 items were scored for “appropriateness” by panel members, discussed face to face, and rescored. Results and limitations: Agreement was reached in 67% of 260 items related to imaging sequence parameters. T2-weighted, dynamic contrast-enhanced, and diffusion-weighted MRI were the key sequences incorporated into the minimum requirements. Consensus was also reached on 54% of 260 items related to image interpretation and reporting, including features of malignancy on individual sequences. A 5-point scale was agreed on for communicating the probability of malignancy, with a minimum of 16 prostatic regions of interest, to include a pictorial representation of suspicious foci. Limitations relate to consensus methodology. Dominant personalities are known to affect the opinions of the group and were countered by a neutral chairperson. Conclusions: Consensus was reached on a number of areas related to the conduct, interpretation, and reporting of mpMRI for the detection, localisation, and characterisation of prostate cancer. Before optimal dissemination of this technology, these outcomes will require formal validation in prospective trials. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
16. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.
- Author
-
Arumainayagam, Nimalan, Kumaar, Senthil, Ahmed, Hashim U., Moore, Caroline M., Payne, Heather, Freeman, Alex, Allen, Clare, Kirkham, Alex, and Emberton, Mark
- Subjects
MAGNETIC resonance imaging ,PROSTATE cancer ,DIAGNOSIS ,RADIOTHERAPY ,DIAGNOSTIC imaging ,BIOPSY ,CANCER relapse ,RADIOLOGISTS - Abstract
OBJECTIVE To assess the role of multiparametric magnetic resonance imaging (mp-MRI) of the prostate in evaluating local recurrence of prostate cancer, using transperineal template-guided 5 mm-spaced biopsies as a reference standard, in men treated with external beam radiotherapy (EBRT) for prostate cancer. PATIENTS AND METHODS The study included 13 patients with evidence of biochemical recurrence after EBRT who had undergone mp-MRI and prostate mapping. Each MRI scan (consisting of T1/T2 weighting, dynamic contrast enhancement and diffusion weighting) was reported by two expert uro-radiologists. Each prostate was divided into four regions of interest (ROI), generating 52 paired datasets for analysis. RESULTS The mean (range) age of the men was 65.5 (55-70) years, the mean prostate-specific antigen (PSA) level before EBRT was 36.6 (4.5-150) ng/mL, the mean time from EBRT to biochemical recurrence was 5.7 (3-10) years and the mean PSA level at the time of recurrence was 7.1 (0.83-27.9) ng/mL. Eleven men had histological evidence of recurrence, with 23 of 52 ROIs involved with cancer. Overall accuracy, as expressed by the area under a receiver-operator curve, was 0.77 and 0.89 for all cancer, with accuracies of 0.86 and 0.93 for those cancers with ≥3 mm biopsy core length. Inter-observer variability was measured by calculating κ coefficients, which showed fair and moderate agreement between radiologists. CONCLUSIONS Interpretation of mpMRI of the prostate after previous EBRT is challenging. Our results show that the accuracy is good using an accurate reference standard. These results need verification in more patients, but have implications for determining presence or absence of local recurrence and subsequent local salvage therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. Diagnostic accuracy of the PROMIS study--Reply.
- Author
-
Ahmed, Hashim U., Brown, Louise C., Kaplan, Richard, Parker, Chris, and Emberton, Mark
- Subjects
- *
MAGNETIC resonance imaging , *PROSTATE cancer , *DIAGNOSIS - Published
- 2017
- Full Text
- View/download PDF
18. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
- Author
-
Ahmed, Hashim U, El-Shater Bosaily, Ahmed, Brown, Louise C, Gabe, Rhian, Kaplan, Richard, Parmar, Mahesh K, Collaco-Moraes, Yolanda, Ward, Katie, Hindley, Richard G, Freeman, Alex, Kirkham, Alex P, Oldroyd, Robert, Parker, Chris, Emberton, Mark, and PROMIS study group
- Subjects
ASTHMA diagnosis ,OSTEOPOROSIS treatment ,PROSTATE tumors ,BIOPSY ,REPORTING of diseases ,OBESITY ,PATIENT decision making ,DIAGNOSIS - Abstract
Background: Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.Methods: We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy]). Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy. The conduct and reporting of each test was done blind to other test results. Clinically significant cancer was defined as Gleason score ≥4 + 3 or a maximum cancer core length 6 mm or longer. This study is registered on ClinicalTrials.gov, NCT01292291.Findings: Between May 17, 2012, and November 9, 2015, we enrolled 740 men, 576 of whom underwent 1·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy. On TPM-biopsy, 408 (71%) of 576 men had cancer with 230 (40%) of 576 patients clinically significant. For clinically significant cancer, MP-MRI was more sensitive (93%, 95% CI 88-96%) than TRUS-biopsy (48%, 42-55%; p<0·0001) and less specific (41%, 36-46% for MP-MRI vs 96%, 94-98% for TRUS-biopsy; p<0·0001). 44 (5·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis.Interpretation: Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers. If subsequent TRUS-biopsies were directed by MP-MRI findings, up to 18% more cases of clinically significant cancer might be detected compared with the standard pathway of TRUS-biopsy for all. MP-MRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter. MP-MRI can also reduce over-diagnosis of clinically insignificant prostate cancer and improve detection of clinically significant cancer.Funding: PROMIS is funded by the UK Government Department of Health, National Institute of Health Research-Health Technology Assessment Programme, (Project number 09/22/67). This project is also supported and partly funded by UCLH/UCL Biomedical Research Centre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL. It is sponsored by University College London (UCL). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
- Author
-
Dickinson, Louise, Ahmed, Hashim U., Hindley, Richard G., McCartan, Neil, Freeman, Alex, Allen, Clare, Emberton, Mark, and Kirkham, Alex P.
- Subjects
- *
PROSTATE-specific antigen , *PROSTATE , *DIAGNOSIS , *PROSTATE cancer , *PROSTATE biopsy , *MEDICAL statistics , *MAGNETIC resonance imaging , *PROSTATE tumors treatment , *BIOPSY , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PHARMACOKINETICS , *PROSTATE tumors , *RESEARCH , *RESEARCH funding , *TIME , *EVALUATION research , *PREDICTIVE tests , *RECEIVER operating characteristic curves , *ABLATION techniques , *TUMOR grading - Abstract
Introduction: Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies. However, there is currently no validated method for monitoring treatment success. We assessed the diagnostic performance of prostate-specific antigen (PSA) parameters and MRI compared to histological outcomes following focal therapy.Patients and Methods: Patients from 3 Ethics Review Board approved prospective studies of focal high intensity-focused ultrasound (HIFU) (Sonablate 500) for localized prostate cancer (T1c-T3a, Gleason grade≤4+3, and PSA≤20). Post-HIFU PSA nadir, 6-month PSA, PSA density, and early (<3wk) and late (6mo) MRI (T2-weighted, dynamic contrast-enhanced±diffusion-weighted) was assessed for predictive accuracy of cancer on postoperative biopsy, using receiver operating characteristic (ROC) analysis and sensitivity, specificity, and positive and negative predictive estimates. ROC areas for MRI and PSA were compared. Calculations for statistical significance (P≤0.05) were obtained in a subset of patients comparing area under ROC for 6-month MRI and PSA criteria, across 4 different histological definitions of disease significance.Results: Of 118 men, 111 underwent at least 1 postoperative biopsy (median 6 cores), with an overall positive biopsy rate of 37% (41/118), over a mean follow-up period of 716 days post-HIFU. Areas under ROC for early and late MRI were (depending on definition of significant disease) 0.65 to 0.76 and 0.77 to 0.85, respectively, with sensitivity, specificity, and negative predictive values of 68% to 91%, 52% to 55%, and 85% to 98% (early MRI), and 63% to 80%, 67% to 73%, and 86% to 97% (late MRI). The area under the ROC curve was statistically significantly higher for late MRI than 6 months and nadir PSA for residual disease >3mm or any Gleason 4 tumor.Conclusions: Early and late MRI performed better than PSA measurements in the detection of residual tumor after focal therapy. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
20. Introduction—Targeting the lesion, not the organ.
- Author
-
Ahmed, Hashim U.
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *PROSTATE cancer treatment , *CANCER radiotherapy , *PROSTATE cancer risk factors , *TREATMENT effectiveness - Abstract
The current diagnostic and therapeutic strategy for localized prostate cancer is not working. In fact, it is severely flawed and, as such, fraught with controversy. Our current strategy has arisen from the imprecision of our diagnostic pathway. We do not know where the cancer is, so we subject the prostate to randomly placed needles in the hope of hitting the tumor. This leads to overdiagnosis, underdiagnosis, missclassification of risk and overtreatment and undertreatment. If we do find cancer, we usually subject the entire prostate to radiotherapy or surgery, which damages the surrounding structures—neurovascular bundles, external urinary sphincter, rectum, and bladder neck. Multiparametric magnetic resonance imaging, coupled with an intensive sampling strategy (targeted biopsies), might be able to rule out clinically significant lesions with a negative predictive value in the order of 90% to 95%. Focal therapy certainly leads to less genitourinary and rectal side effects. Current data from more than 3,000 men treated internationally show that incontinence after focal therapy is 0% to 5% (radical therapy can lead to incontinence in 15%–20%) whereas erectile dysfunction occurs in 5% to 10% of men with good baseline function (radical therapy rates vary between 30% and 60%). Early to medium cancer control using biopsies after treatment shows between 80% and 90% of patients have a successful treatment, with 10% to 15% of men requiring redo-treatment with minimal additional morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. The PROMIS of MRI.
- Author
-
Ahmed, Hashim U.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PROSTATE cancer treatment , *ACCURACY of measuring instruments , *REPRODUCIBLE research , *MAGNETIC resonance imaging - Abstract
The author criticizes the results of the PROstate MR Imaging Study (PROMIS) for diagnosis and treatment of a cancer. These include the inaccurativeness of the retrospective data provided for the significance disease, lack of reproducibility for the external expert centers, and its incapability to implement on Tesla scanners.
- Published
- 2016
- Full Text
- View/download PDF
22. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?
- Author
-
Abd-Alazeez, Mohamed, Ahmed, Hashim U, Arya, Manit, Charman, Susan C, Anastasiadis, Eleni, Freeman, Alex, Emberton, Mark, and Kirkham, Alex
- Subjects
- *
ANTHROPOMETRY , *BIOPSY , *MAGNETIC resonance imaging , *PROGNOSIS , *PROSTATE , *PROSTATE tumors , *RESEARCH funding , *ULTRASONIC therapy , *PROSTATE-specific antigen , *DIAGNOSIS ,RESEARCH evaluation - Abstract
Purpose: To assess the performance of multiparametric magnetic resonance imaging (mp-MRI) in patients with previous negative transrectal ultrasound (TRUS) guided prostate biopsy.Materials and Methods: Fifty-four patients with at least 1 previous negative TRUS prostate biopsy underwent mp-MRI in the form of T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging. This was followed by transperineal template systematic prostate biopsies. Analysis was done based on 2 sectors per prostate, right and left (108 sectors out of 54 prostates). mp-MRI was scored using an ordinal scale 1 to 5 based on the suspicion of the presence of clinically significant disease. We used 6 different definitions for clinically significant disease and tested the performance of mp-MRI at each single definition.Results: Median age was 64 (range, 39-75), median PSA level was 10 (range, 2-23), and median number of biopsies was 45 (range, 21-137). Cancer of any volume and any grade was detected in 34 of 54 (63%) patients. mp-MRI accuracy at detection of clinically significant cancer using University College London (UCL) definition 2 (any Gleason score of 4 or maximum cancer core length of ≥ 4 mm or both) showed sensitivity of 76%, specificity of 42%, positive predictive value of 38%, and negative predictive value of 79%. For a different definition of significant tumor (UCL definition 1; dominant Gleason score 4 or maximum cancer core length ≥ 6 mm or both), the sensitivity was 90%, specificity 42%, positive predictive value 26%, and negative predictive value 95%.Conclusions: mp-MRI showed good performance at both detection and ruling out clinically significant disease, according to the definition used. mp-MRI can then be used as a triage test in the population with persistently elevated or rising PSA levels to select patients that can avoid unnecessary prostate biopsy. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
23. Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study.
- Author
-
Robertson, Nicola L., Hu, Yipeng, Ahmed, Hashim U., Freeman, Alex, Barratt, Dean, and Emberton, Mark
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *BIOPSY , *COMPUTER simulation , *STATISTICAL significance , *MAGNETIC resonance imaging of cancer , *PROSTATECTOMY , *IMAGING of cancer - Abstract
Abstract: Background: Prostate biopsy parameters are commonly used to attribute cancer risk. A targeted approach to lesions found on imaging may have an impact on the risk attribution given to a man. Objective: To evaluate whether, based on computer simulation, targeting of lesions during biopsy results in reclassification of cancer risk when compared with transrectal ultrasound (TRUS) guided biopsy. Design, setting, and participants: A total of 107 reconstructed three-dimensional models of whole-mount radical prostatectomy specimens were used for computer simulations. Systematic 12-core TRUS biopsy was compared with transperineal targeted biopsies using between one and five cores. All biopsy strategies incorporated operator and needle deflection error. A target was defined as any lesion ≥0.2ml. A false-positive magnetic resonance imaging identification rate of 34% was applied. Outcome measurements and statistical analysis: Sensitivity was calculated for the detection of all cancer and clinically significant disease. Cases were designated as high risk based on achieving ≥6mm cancer length and/or ≥50% positive cores. Statistical significance (p values) was calculated using both a paired Kolmogorov-Smirnov test and the t test. Results and limitations: When applying a widely used biopsy criteria to designate risk, 12-core TRUS biopsy classified only 24% (20 of 85) of clinically significant cases as high risk, compared with 74% (63 of 85) of cases using 4 targeted cores. The targeted strategy reported a significantly higher proportion of positive cores (44% vs 11%; p <0.0001) and a significantly greater mean maximum cancer core length (7.8mm vs 4.3mm; p <0.0001) when compared with 12-core TRUS biopsy. Computer simulations may not reflect the sources of errors encountered in clinical practice. To mitigate this we incorporated all known major sources of error to maximise clinical relevance. Conclusions: Image-targeted biopsy results in an increase in risk attribution if traditional criteria, based on cancer core length and the proportion of positive cores, are applied. Targeted biopsy strategies will require new risk stratification models that account for the increased likelihood of sampling the tumour. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
24. Systematic Review of Complications of Prostate Biopsy▪.
- Author
-
Loeb, Stacy, Vellekoop, Annelies, Ahmed, Hashim U., Catto, James, Emberton, Mark, Nam, Robert, Rosario, Derek J., Scattoni, Vincenzo, and Lotan, Yair
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *BIOPSY , *SYSTEMATIC reviews , *PROSTATE cancer treatment , *EARLY detection of cancer , *SURGICAL complications - Abstract
Abstract: Context: Prostate biopsy is commonly performed for cancer detection and management. The benefits and risks of prostate biopsy are germane to ongoing debates about prostate cancer screening and treatment. Objective: To perform a systematic review of complications from prostate biopsy. Evidence acquisition: A literature search was performed using PubMed and Embase, supplemented with additional references. Articles were reviewed for data on the following complications: hematuria, rectal bleeding, hematospermia, infection, pain, lower urinary tract symptoms (LUTS), urinary retention, erectile dysfunction, and mortality. Evidence synthesis: After biopsy, hematuria and hematospermia are common but typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare. Conclusions: Preparation for biopsy should include antimicrobial prophylaxis and pain management. Prostate biopsy is frequently associated with minor bleeding and urinary symptoms that usually do not require intervention. Infectious complications can be serious, requiring prompt management and continued work into preventative strategies. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
25. Nanotechnology and Its Relevance to the Urologist
- Author
-
Gommersall, Lyndon, Shergill, Iqbal S., Ahmed, Hashim U., Hayne, Dickon, Arya, Manit, Patel, Hitendra R.H., Hashizume, Makoto, and Gill, Inderbir S.
- Subjects
- *
NANOTECHNOLOGY , *UROLOGY , *DRUG delivery systems , *CANCER diagnosis , *MEDICAL research - Abstract
Abstract: Objectives: We review important aspects of nanotechnology, and discuss the wide range of research and clinical applications of nanomedicine in the field of urology. There is particular emphasis on key clinical and pre-clinical studies to provide an update on recent and potential applications in the care of urological patients. Methods: A directed Medline literature review of nanotechnology was performed. Important publications that have shaped our understanding of nanotechnology were selected for review and were augmented by manual searches of reference lists. Results: Nanotechnology is the study, design, creation, synthesis, manipulation, and application of functional materials, devices, and systems through control of matter at the nanometer scale. Studies demonstrate a number of important concepts. These include nanovectors, nanotubes, and nanosensors for targeted drug delivery; nanowires and nanocantilever arrays for early detection of precancerous and malignant lesions; and nanopores for DNA sequencing. These advances will lead to significant applications relevant to the diagnosis, management, and treatment of all urological conditions. Conclusions: This review is designed for the urologist to provide an overview and update on nanotechnology and its applications in the field of urology. In the future, it is widely expected that nanotechnology and nanomedicine will have a significant impact on urological research and clinical practice, allowing urologists to intervene at the cellular and molecular level. With structured, safe implementation, nanotechnologies have the potential to revolutionise urological practice in our lifetime. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
26. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
- Author
-
Sathianathen, Niranjan J., Omer, Altan, Harriss, Eli, Davies, Lucy, Kasivisvanathan, Veeru, Punwani, Shonit, Moore, Caroline M., Kastner, Christof, Barrett, Tristan, Van Den Bergh, Roderick CN, Eddy, Ben A., Gleeson, Fergus, Macpherson, Ruth, Bryant, Richard J., Catto, James W.F., Murphy, Declan G., Hamdy, Freddie C., Ahmed, Hashim U., and Lamb, Alastair D.
- Subjects
- *
MAGNETIC resonance imaging , *PROSTATE cancer , *CANCER diagnosis , *META-analysis , *PROSTATE-specific antigen - Abstract
: Prebiopsy multiparametric magnetic resonance imaging (mpMRI) is increasingly used in prostate cancer diagnosis. The reported negative predictive value (NPV) of mpMRI is used by some clinicians to aid in decision making about whether or not to proceed to biopsy. : We aim to perform a contemporary systematic review that reflects the latest literature on optimal mpMRI techniques and scoring systems to update the NPV of mpMRI for clinically significant prostate cancer (csPCa). : We conducted a systematic literature search and included studies from 2016 to September 4, 2019, which assessed the NPV of mpMRI for csPCa, using biopsy or clinical follow-up as the reference standard. To ensure that studies included in this analysis reflect contemporary practice, we only included studies in which mpMRI findings were interpreted according to the Prostate Imaging Reporting and Data System (PIRADS) or similar Likert grading system. We define negative mpMRI as either (1) PIRADS/Likert 1–2 or (2) PIRADS/Likert 1–3; csPCa was defined as either (1) Gleason grade group ≥2 or (2) Gleason grade group ≥3. We calculated NPV separately for each combination of negative mpMRI and csPCa. : A total of 42 studies with 7321 patients met our inclusion criteria and were included for analysis. Using definition (1) for negative mpMRI and csPCa, the pooled NPV for biopsy-naïve men was 90.8% (95% confidence interval [CI] 88.1–93.1%). When defining csPCa using definition (2), the NPV for csPCa was 97.1% (95% CI 94.9–98.7%). Calculation of the pooled NPV using definition (2) for negative mpMRI and definition (1) for csPCa yielded the following: 86.8% (95% CI 80.1–92.4%). Using definition (2) for both negative mpMRI and csPCa, the pooled NPV from two studies was 96.1% (95% CI 93.4–98.2%). : Multiparametric MRI of the prostate is generally an accurate test for ruling out csPCa. However, we observed heterogeneity in the NPV estimates, and local institutional data should form the basis of decision making if available. : The negative predictive values should assist in decision making for clinicians considering not proceeding to biopsy in men with elevated age-specific prostate-specific antigen and multiparametric magnetic resonance imaging reported as negative (or equivocal) on Prostate Imaging Reporting and Data System/Likert scoring. Some 7–10% of men, depending on the setting, will miss a diagnosis of clinically significant cancer if they do not proceed to biopsy. Given the institutional variation in results, it is of upmost importance to base decision making on local data if available. Depending on definition of "negative multiparametric magnetic resonance imaging" and "clinically significant prostate cancer", the negative predictive value ranged from 84% to 97%, suggesting that it is a reliable test to rule out clinically significant prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. The CADMUS trial – Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer.
- Author
-
Grey, Alistair, Scott, Rebecca, Charman, Susan, van der Meulen, Jan, Frinking, Peter, Acher, Peter, Liyanage, Sidath, Madaan, Sanjeev, Constantinescu, Gabriel, Shah, Bina, Graves, Chris Brew, Freeman, Alex, Jameson, Charles, Ramachandran, Navin, Emberton, Mark, Arya, Manit, and Ahmed, Hashim U.
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *PROSTATE , *PROSTATE biopsy , *PROSTATE cancer treatment , *CLINICAL trials , *MAGNETIC resonance imaging - Abstract
Objective To compare the proportion of clinically significant prostate cancers (PCa) found in lesions detected by multiparametric MRI (mpMRI) with that found in lesions detected by multiparametric ultrasound (mpUSS), in men at risk. Patients and methods CADMUS (Cancer Detection by Multiparametric Ultrasound of the prostate) is a prospective, multi-centre paired cohort diagnostic utility study with built-in randomisation of order of biopsies. The trial is registered ISRCTN38541912. All patients will undergo the index test under evaluation (mpUSS ± biopsies), as well as the standard test (mpMRI ± biopsies). Eligible men will be those at risk of harbouring prostate cancer usually recommended for prostate biopsy, either for the first time or as a repeat, who have not had any prior treatment for prostate cancer. Men in need of repeat biopsy will include those with prior negative results but ongoing suspicion, and those with an existing prostate cancer diagnosis but a need for accurate risk stratification. Both scans will be reported blind to the results of the other and the order in which the targeted biopsies derived from the two different imaging modalities are taken will be randomised. Comparison will be drawn between biopsy results of lesions detected by mpUSS with those lesions detected by mpMRI. Agreement over position between the two imaging modalities will be studied. Discussion CADMUS will provide level one evidence on the performance of mpUSS derived targeted biopsies in the identification of clinically significant prostate cancer in comparison to mpMRI targeted biopsies. Recruitment is underway and expected to complete in 2018. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
- Author
-
Faria, Rita, Soares, Marta O., Spackman, Eldon, Ahmed, Hashim U., Brown, Louise C., Kaplan, Richard, Emberton, Mark, and Sculpher, Mark J.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *ENDORECTAL ultrasonography , *COST effectiveness , *BIOPSY , *MAGNETIC resonance imaging - Abstract
Background The current recommendation of using transrectal ultrasound-guided biopsy (TRUSB) to diagnose prostate cancer misses clinically significant (CS) cancers. More sensitive biopsies (eg, template prostate mapping biopsy [TPMB]) are too resource intensive for routine use, and there is little evidence on multiparametric magnetic resonance imaging (MPMRI). Objective To identify the most effective and cost-effective way of using these tests to detect CS prostate cancer. Design, setting, and participants Cost-effectiveness modelling of health outcomes and costs of men referred to secondary care with a suspicion of prostate cancer prior to any biopsy in the UK National Health Service using information from the diagnostic Prostate MR Imaging Study (PROMIS). Intervention Combinations of MPMRI, TRUSB, and TPMB, using different definitions and diagnostic cut-offs for CS cancer. Outcome measurements and statistical analysis Strategies that detect the most CS cancers given testing costs, and incremental cost-effectiveness ratios (ICERs) in quality-adjusted life years (QALYs) given long-term costs. Results and limitations The use of MPMRI first and then up to two MRI-targeted TRUSBs detects more CS cancers per pound spent than a strategy using TRUSB first (sensitivity = 0.95 [95% confidence interval {CI} 0.92–0.98] vs 0.91 [95% CI 0.86–0.94]) and is cost effective (ICER = £7,076 [€8350/QALY gained]). The limitations stem from the evidence base in the accuracy of MRI-targeted biopsy and the long-term outcomes of men with CS prostate cancer. Conclusions An MPMRI-first strategy is effective and cost effective for the diagnosis of CS prostate cancer. These findings are sensitive to the test costs, sensitivity of MRI-targeted TRUSB, and long-term outcomes of men with cancer, which warrant more empirical research. This analysis can inform the development of clinical guidelines. Patient summary We found that, under certain assumptions, the use of multiparametric magnetic resonance imaging first and then up to two transrectal ultrasound-guided biopsy is better than the current clinical standard and is good value for money. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. A randomized controlled trial to investigate magnetic resonance imaging–targeted biopsy as an alternative diagnostic strategy to transrectal ultrasound–guided prostate biopsy in the diagnosis of prostate cancer.
- Author
-
Kasivisvanathan, Veeru, Arya, Manit, Ahmed, Hashim U., Moore, Caroline M., and Emberton, Mark
- Subjects
- *
MAGNETIC resonance imaging , *PROSTATE cancer , *DIAGNOSIS , *ENDORECTAL ultrasonography - Published
- 2015
- Full Text
- View/download PDF
30. Clinical utility of transperineal template-guided mapping biopsy of the prostate after negative magnetic resonance imaging−guided transrectal biopsy.
- Author
-
Sivaraman, Arjun, Sanchez-Salas, Rafael, Ahmed, Hashim U., Barret, Eric, Cathala, Nathalie, Mombet, Annick, Uriburu Pizarro, Facundo, Carneiro, Arie, Doizi, Steeve, Galiano, Marc, Rozet, Francois, Prapotnich, Dominique, and Cathelineau, Xavier
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *BIOPSY , *MAGNETIC resonance imaging of cancer , *PROSTATE cancer patients , *PROSTATE-specific antigen , *MEDICAL protocols - Abstract
Purpose We evaluated the prostate cancer detection with transperineal template-guided mapping biopsy in patients with elevated prostate-specific antigen and negative magnetic resonance imaging (MRI)−guided biopsy. Materials and methods Totally 75 patients underwent transperineal template-guided mapping biopsy for prior negative MRI−guided (cognitive registration) biopsy during April 2013 to August 2014. Primary objective was to report clinically significant cancer detection in this cohort of patients. Significant cancer was defined using varying thresholds of MCL or Gleason grade 3+4 or greater or both. Cancers with more than 80% of positive core length anterior to the level of urethra were termed anterior zone cancer. Secondary objective was to evaluate the potential clinical and radiological predictors for significant cancer detection. Results The mean age was 61.6±6.5 years and median prostate-specific antigen was 10.4 ng/dl (7.9−18) with a mean MRI target size of 7.2 mm (4−11). Transperineal template-guided mapping biopsy identified cancer in 36% (27/75) patients and 66.6% (18/27) of them were anterior zone cancers. The rates of detection of clinically significant and insignificant cancer according to the several definitions used range from 22.7% to 30.7% and 5.3% to 13.3%, respectively. Multivariate analysis did not identify any predictors for finding clinically significant and anterior cancers in this group of patients. Conclusion Transperineal template-guided mapping biopsy appears to be an excellent biopsy protocol for downstream management following negative MRI−guided biopsy. Most of the cancers detected were predominantly anterior tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound–Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies. Eur Urol 2014;66:22–9
- Author
-
Shanmugabavan, Yaalini, Guillaumier, Stephanie, and Ahmed, Hashim U.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *RECTAL diseases , *ULTRASONIC imaging , *BIOPSY , *COMPARATIVE studies , *LONGITUDINAL method , *MAGNETIC resonance imaging - Published
- 2015
- Full Text
- View/download PDF
32. Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
- Author
-
David Atkinson, Keith Burling, Peter Barker, Manuel Rodriguez-Justo, Urszula Stopka-Farooqui, Lina M. Carmona Echeverria, Aiman Haider, Eoin Dinneen, Mark Emberton, Hayley Pye, Hashim U. Ahmed, Joseph M. Norris, Mrishta Brizmohun Appayya, Greg Shaw, Caroline M. Moore, Hayley C. Whitaker, Alistair Grey, Joey Clemente, Shonit Punwani, Arash Latifoltojar, Alex Kirkham, Susan Heavey, Saurabh Singh, David J. Hawkes, N Stevens, Edward W. Johnston, Alex Freeman, Eleftheria Panagiotaki, Elly Pilavachi, Tony Ng, Benjamin S. Simpson, Elisenda Bonet-Carne, Dominic Patel, Daniel C. Alexander, Vasilis Stavrinides, Clare Allen, Teresita Beeston, Pye, Hayley [0000-0001-7042-5416], Singh, Saurabh [0000-0002-8730-524X], Norris, Joseph M [0000-0003-2294-0303], Carmona Echeverria, Lina M [0000-0001-6546-8980], Heavey, Susan [0000-0002-2974-4578], Simpson, Benjamin S [0000-0003-3685-6110], Bonet-Carne, Elisenda [0000-0003-0567-6141], Patel, Dominic [0000-0001-9223-6632], Alexander, Daniel C [0000-0003-2439-350X], Haider, Aiman [0000-0001-5007-1761], Allen, Clare [0000-0003-1124-6666], Beeston, Teresita [0000-0003-3480-2100], Ahmed, Hashim U [0000-0003-0202-7912], Whitaker, Hayley C [0000-0002-2695-0202], and Apollo - University of Cambridge Repository
- Subjects
Cancer Research ,medicine.medical_specialty ,Prostate biopsy ,diagnosis ,Psa density ,030232 urology & nephrology ,Urology ,multiparametric MRI ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Multiparametric Magnetic Resonance Imaging ,RC254-282 ,medicine.diagnostic_test ,INNOVATE ,business.industry ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,biomarkers ,medicine.disease ,prostate cancer ,PSA density ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,business - Abstract
Objectives: To assess the clinical outcomes of mpMRI before biopsy and evaluate the space remaining for novel biomarkers. Methods: The INNOVATE study was set up to evaluate the validity of novel fluidic biomarkers in men with suspected prostate cancer who undergo pre-biopsy mpMRI. We report the characteristics of this clinical cohort, the distribution of clinical serum biomarkers, PSA and PSA density (PSAD), and compare the mpMRI Likert scoring system to the Prostate Imaging–Reporting and Data System v2.1 (PI-RADS) in men undergoing biopsy. Results: 340 men underwent mpMRI to evaluate suspected prostate cancer. 193/340 (57%) men had subsequent MRI-targeted prostate biopsy. Clinically significant prostate cancer (csigPCa), i.e., overall Gleason ≥ 3 + 4 of any length OR maximum cancer core length (MCCL) ≥4 mm of any grade including any 3 + 3, was found in 96/195 (49%) of biopsied patients. Median PSA (and PSAD) was 4.7 (0.20), 8.0 (0.17), and 9.7 (0.31) ng/mL (ng/mL/mL) in mpMRI scored Likert 3,4,5 respectively for men with csigPCa on biopsy. The space for novel biomarkers was shown to be within the group of men with mpMRI scored Likert3 (178/340) and 4 (70/350), in whom an additional of 40% (70/178) men with mpMRI-scored Likert3, and 37% (26/70) Likert4 could have been spared biopsy. PSAD is already considered clinically in this cohort to risk stratify patients for biopsy, despite this 67% (55/82) of men with mpMRI-scored Likert3, and 55% (36/65) Likert4, who underwent prostate biopsy had a PSAD below a clinical threshold of 0.15 (or 0.12 for men aged <, 50 years). Different thresholds of PSA and PSAD were assessed in mpMRI-scored Likert4 to predict csigPCa on biopsy, to achieve false negative levels of ≤5% the proportion of patients whom who test as above the threshold were unsuitably high at 86 and 92% of patients for PSAD and PSA respectively. When PSA was re tested in a sub cohort of men repeated PSAD showed its poor reproducibility with 43% (41/95) of patients being reclassified. After PI-RADS rescoring of the biopsied lesions, 66% (54/82) of the Likert3 lesions received a different PI-RADS score. Conclusions: The addition of simple biochemical and radiological markers (Likert and PSAD) facilitate the streamlining of the mpMRI-diagnostic pathway for suspected prostate cancer but there remains scope for improvement, in the introduction of novel biomarkers for risk assessment in Likert3 and 4 patients, future application of novel biomarkers tested in a Likert cohort would also require re-optimization around Likert3/PI-RADS2, as well as reproducibility testing.
- Published
- 2021
33. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging–Ultrasound Fusion Targeted Biopsy: A Systematic Review.
- Author
-
Valerio, Massimo, Donaldson, Ian, Emberton, Mark, Ehdaie, Behfar, Hadaschik, Boris A., Marks, Leonard S., Mozer, Pierre, Rastinehad, Ardeshir R., and Ahmed, Hashim U.
- Subjects
- *
PROSTATE cancer patients , *BIOPSY , *MAGNETIC resonance imaging , *SYSTEMATIC reviews , *DIAGNOSIS , *PROSTATE cancer , *ENDORECTAL ultrasonography , *COMPARATIVE studies , *META-analysis - Abstract
Context The current standard for diagnosing prostate cancer in men at risk relies on a transrectal ultrasound–guided biopsy test that is blind to the location of the cancer. To increase the accuracy of this diagnostic pathway, a software-based magnetic resonance imaging–ultrasound (MRI-US) fusion targeted biopsy approach has been proposed. Objective Our main objective was to compare the detection rate of clinically significant prostate cancer with software-based MRI-US fusion targeted biopsy against standard biopsy. The two strategies were also compared in terms of detection of all cancers, sampling utility and efficiency, and rate of serious adverse events. The outcomes of different targeted approaches were also compared. Evidence acquisition We performed a systematic review of PubMed/Medline, Embase (via Ovid), and Cochrane Review databases in December 2013 following the Preferred Reported Items for Systematic reviews and Meta-analysis statement. The risk of bias was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Evidence synthesis Fourteen papers reporting the outcomes of 15 studies ( n = 2293; range: 13–582) were included. We found that MRI-US fusion targeted biopsies detect more clinically significant cancers (median: 33.3% vs 23.6%; range: 13.2–50% vs 4.8–52%) using fewer cores (median: 9.2 vs 37.1) compared with standard biopsy techniques, respectively. Some studies showed a lower detection rate of all cancer (median: 50.5% vs 43.4%; range: 23.7–82.1% vs 14.3–59%). MRI-US fusion targeted biopsy was able to detect some clinically significant cancers that would have been missed by using only standard biopsy (median: 9.1%; range: 5–16.2%). It was not possible to determine which of the two biopsy approaches led most to serious adverse events because standard and targeted biopsies were performed in the same session. Software-based MRI-US fusion targeted biopsy detected more clinically significant disease than visual targeted biopsy in the only study reporting on this outcome (20.3% vs 15.1%). Conclusions Software-based MRI-US fusion targeted biopsy seems to detect more clinically significant cancers deploying fewer cores than standard biopsy. Because there was significant study heterogeneity in patient inclusion, definition of significant cancer, and the protocol used to conduct the standard biopsy, these findings need to be confirmed by further large multicentre validating studies. Patient summary We compared the ability of standard biopsy to diagnose prostate cancer against a novel approach using software to overlay the images from magnetic resonance imaging and ultrasound to guide biopsies towards the suspicious areas of the prostate. We found consistent findings showing the superiority of this novel targeted approach, although further high-quality evidence is needed to change current practice. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
- Author
-
Valerio, Massimo, Dickinson, Louise, Ali, Afia, Ramachandran, Navin, Donaldson, Ian, Freeman, Alex, Ahmed, Hashim U., and Emberton, Mark
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PROSTATE cancer treatment , *ELECTROPORATION , *ABLATION techniques , *ADVERSE health care events , *GENITOURINARY organs , *HEALTH outcome assessment , *LONGITUDINAL method - Abstract
Introduction Focal therapy may reduce the toxicity of current radical treatments while maintaining the oncological benefit. Irreversible electroporation (IRE) has been proposed to be tissue selective and so might have favourable characteristics compared to the currently used prostate ablative technologies. The aim of this trial is to determine the adverse events, genito-urinary side effects and early histological outcomes of focal IRE in men with localised prostate cancer. Methods This is a single centre prospective development (stage 2a) study following the IDEAL recommendations for evaluating new surgical procedures. Twenty men who have MRI-visible disease localised in the anterior part of the prostate will be recruited. The sample size permits a precision estimate around key functional outcomes. Inclusion criteria include PSA ≤ 15 ng/ml, Gleason score ≤ 4 + 3, stage T2N0M0 and absence of clinically significant disease outside the treatment area. Treatment delivery will be changed in an adaptive iterative manner so as to allow optimisation of the IRE protocol. After focal IRE, men will be followed during 12 months using validated patient reported outcome measures (IPSS, IIEF-15, UCLA-EPIC, EQ-5D, FACT-P, MAX-PC). Early disease control will be evaluated by mpMRI and targeted transperineal biopsy of the treated area at 6 months. Discussion The NEAT trial will assess the early functional and disease control outcome of focal IRE using an adaptive design. Our protocol can provide guidance for designing an adaptive trial to assess new surgical technologies in the challenging landscape of health technology assessment in prostate cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Defining the level of evidence for technology adoption in the localized prostate cancer pathway.
- Author
-
Valerio, Massimo, Bosaily, Ahmed El-Shater, Emberton, Mark, and Ahmed, Hashim U.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PROSTATE cancer treatment , *EARLY detection of cancer , *CLINICAL trials , *HEALTH outcome assessment , *MEDICAL technology - Abstract
New technologies in prostate cancer are attempting to change the current prostate cancer pathway by aiming to reduce harms while maintaining the benefits associated with screening, diagnosis, and treatment. In this article, we discuss the optimal evaluation that new technologies should undergo to provide level 1 evidence typically required to change the practice. With this in mind, we focus on feasible and pragmatic trials that could be delivered in a timely fashion by many centers while retaining primary outcomes that focus on clinically meaningful outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses.
- Author
-
Peters, Max, Kanthabalan, Abi, Shah, Taimur T., McCartan, Neil, Moore, Caroline M., Arya, Manit, van der Voort van Zyp, Jochem R., Moerland, Marinus A., Hindley, Richard G., Emberton, Mark, and Ahmed, Hashim U.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *BIOCHEMISTRY , *PREDICTION models , *PROSTATE , *DIAGNOSTIC imaging , *MAGNETIC resonance imaging , *PROSTATE tumors treatment , *CANCER relapse , *LONGITUDINAL method , *RESEARCH methodology , *PROGNOSIS , *PROSTATE tumors , *RESEARCH funding , *ULTRASONIC therapy , *RELATIVE medical risk , *TREATMENT effectiveness - Abstract
Purpose: Patient selection for focal salvage remains difficult. Therefore, we developed and internally validated prediction models for biochemical failure (BF) and a composite endpoint (CE) following focal salvage high intensity focused ultrasound (HIFU) for radiorecurrent prostate cancer.Materials and Methods: A prospective HIFU registry identified 150 cases (November 2006-August 2015). Recurrence was assessed with multiparametric magnetic resonance imaging (MRI) combined with template prostate mapping biopsies, targeted biopsies, or systematic transrectal ultrasound-guided biopsies. Metastatic disease was ruled out with a positron emission tomography-computed tomography and a bone scan. Focal salvage HIFU consisted of quadrant-ablation, hemi-ablation, or index-lesion ablation. Cox-regression was used for BF (Phoenix-definition) and CE (BF/MRI+/biopsies+/local or systemic treatment/metastases+/prostate cancer specific mortality+). Internal validation was performed using bootstrap resampling (500 datasets) after which C-statistic and hazard ratios were adjusted. Models were calibrated and risk scores created.Results: Median follow-up was 35 months (interquartile range: 22-52). Median biochemical disease-free survival (DFS) was 33 months (95% CI: 23-45). Median CE-free survival was 24 months (95% CI: 21-35). After multivariable analysis, DFS interval after primary radiotherapy, presalvage prostate-specific antigen (PSA), PSA-doubling time, prostatic volume, and T-stage (both MRI based) predicted BF. For the CE, PSA-doubling time was not predictive but additionally, primary Gleason score was. The adjusted C-statistics were 0.68 and 0.64 for BF and CE, respectively. Calibration was accurate until 48 months. The risk scores showed 3 groups, with biochemical DFS of 60%, 35%, and 7% and CE-free survival of 40%, 24%, and 0% at 4 years.Conclusion: Our model, once externally validated, could allow for better selection of patients for focal salvage HIFU. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
37. Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer.
- Author
-
Valerio, Massimo, McCartan, Neil, Freeman, Alex, Punwani, Shonit, Emberton, Mark, and Ahmed, Hashim U.
- Subjects
- *
PROSTATE tumors , *BIOPSY , *COMPUTER software , *UROLOGICAL surgery , *LONGITUDINAL method , *MAGNETIC resonance imaging , *RESEARCH funding , *PILOT projects , *COMPUTER-assisted surgery , *DIAGNOSIS - Abstract
Objectives: Targeted biopsy based on cognitive or software magnetic resonance imaging (MRI) to transrectal ultrasound registration seems to increase the detection rate of clinically significant prostate cancer as compared with standard biopsy. However, these strategies have not been directly compared against an accurate test yet. The aim of this study was to obtain pilot data on the diagnostic ability of visually directed targeted biopsy vs. software-based targeted biopsy, considering transperineal template mapping (TPM) biopsy as the reference test.Methods and Materials: Prospective paired cohort study included 50 consecutive men undergoing TPM with one or more visible targets detected on preoperative multiparametric MRI. Targets were contoured on the Biojet software. Patients initially underwent software-based targeted biopsies, then visually directed targeted biopsies, and finally systematic TPM. The detection rate of clinically significant disease (Gleason score ≥3+4 and/or maximum cancer core length ≥4mm) of one strategy against another was compared by 3×3 contingency tables. Secondary analyses were performed using a less stringent threshold of significance (Gleason score ≥4+3 and/or maximum cancer core length ≥6mm).Results: Median age was 68 (interquartile range: 63-73); median prostate-specific antigen level was 7.9ng/mL (6.4-10.2). A total of 79 targets were detected with a mean of 1.6 targets per patient. Of these, 27 (34%), 28 (35%), and 24 (31%) were scored 3, 4, and 5, respectively. At a patient level, the detection rate was 32 (64%), 34 (68%), and 38 (76%) for visually directed targeted, software-based biopsy, and TPM, respectively. Combining the 2 targeted strategies would have led to detection rate of 39 (78%). At a patient level and at a target level, software-based targeted biopsy found more clinically significant diseases than did visually directed targeted biopsy, although this was not statistically significant (22% vs. 14%, P = 0.48; 51.9% vs. 44.3%, P = 0.24). Secondary analysis showed similar results. Based on these findings, a paired cohort study enrolling at least 257 men would verify whether this difference is statistically significant.Conclusion: The diagnostic ability of software-based targeted biopsy and visually directed targeted biopsy seems almost comparable, although utility and efficiency both seem to be slightly in favor of the software-based strategy. Ongoing trials are sufficiently powered to prove or disprove these findings. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.